LB Pharmaceuticals (LBRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.80
- Surprise
- —
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54 — benzinga, 2026-08-12
- LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates LBRX Sell at 5.4/10; no pre/post engine snapshot brackets this report.
0 of the last 3 quarters beat the estimate. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: LB-102
- Quality below floor (1.6 < 4.0)
- Momentum score 3.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $34.26
- Price target
- $47.66
- Stop
- $32.72
- Upside to target
- +39.1%
- Reward-to-risk
- 3.5:1
Risk check: RSI 19 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
LBRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.12B
- P/E (fwd)
- -6.7
- P/E (ttm)
- 346.2
- 52-week range
- $14.32–$50.16
- Off 52-week high
- 31.7%
- RSI (14)
- 19
- Volume vs avg
- 1.18×
- Score today
- 5.4/10